Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2006;156(5):130–141. doi: 10.1007/s10354-006-0267-8

Immunizations in the elderly: do they live up to their promise?

Impfungen bei älteren Menschen – halten sie was sie versprechen?

Dietmar Herndler-Brandstetter 1, Daniel P Cioca 1, Beatrix Grubeck-Loebenstein 2,✉
PMCID: PMC7088340  PMID: 16823527

Summary

In the 21st century, public health is not only challenged by newly emerging and re-emerging infectious diseases but also by demographic developments that are taking place in many countries. Importantly, infections in the elderly are more frequent, more severe and have distinct features with respect to clinical presentation and treatment. This is due to a decline in the functions of the immune system referred to as immunosenescence. The most important age-related changes affect the T cell system. Although this derogates the protective effect of some vaccines, vaccinations are still considered the most cost-effective medical procedure for preventing morbidity and mortality caused by infectious diseases. The present article aims at outlining the impact of infectious diseases on the elderly and summarizing the progress made in the field of vaccinations of the elderly and how age-related changes within the immune system contribute to the decreased efficacy of vaccines.

Keywords: Vaccination, Aging, Immune system

References

  1. Fenner F. A successful eradication campaign. Global eradication of smallpox. Rev Infect Dis. 1982;4:916–930. doi: 10.1093/clinids/4.5.916. [DOI] [PubMed] [Google Scholar]
  2. Pharmaceutical Research and Manufacturers of America, 2004 Survey: New Medicines in development for Infectious diseases, http://www.phrma.org/newmedicines/resources/2004-04-22.130.pdf
  3. Cerny T. Anti-nicotine vaccination: where are we? Recent Results Cancer Res. 2005;166:167–175. doi: 10.1007/3-540-26980-0_12. [DOI] [PubMed] [Google Scholar]
  4. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5:296–306. doi: 10.1038/nri1592. [DOI] [PubMed] [Google Scholar]
  5. Shoenfeld Y, Sherer Y, Harats D. Artherosclerosis as an infectious, inflammatory and autoimmune disease. Trends Immunol. 2001;22:293–295. doi: 10.1016/S1471-4906(01)01922-6. [DOI] [PubMed] [Google Scholar]
  6. Weyand CM, Fulbright JW, Goronzy JJ. Immunosenescence, autoimmunity, and rheumatoid arthritis. Exp Gerontol. 2003;38:833–841. doi: 10.1016/S0531-5565(03)00090-1. [DOI] [PubMed] [Google Scholar]
  7. Blasko I, Grubeck-Loebenstein B. Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease. Drugs Aging. 2003;20:101–113. doi: 10.2165/00002512-200320020-00002. [DOI] [PubMed] [Google Scholar]
  8. Blasko I, Stampfer-Kountchev M, Robatscher P, Veerhuis R, Eikelenboom P, Grubeck-Loebenstein B. How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell. 2004;3:169–176. doi: 10.1111/j.1474-9728.2004.00101.x. [DOI] [PubMed] [Google Scholar]
  9. Weiss RA, McMichael AJ. Social and environmental risk factors in the emergence of infectious diseases. Nat Med. 2004;10:S70–S76. doi: 10.1038/nm1150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. 2004. World Health Report
  11. Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis. 2002;2:659–666. doi: 10.1016/S1473-3099(02)00437-1. [DOI] [PubMed] [Google Scholar]
  12. Barker WH, Mullooly JP. Pneumonia and influenza deaths during epidemics: implications for prevention. Arch Intern Med. 1982;142:85–89. doi: 10.1001/archinte.142.1.85. [DOI] [PubMed] [Google Scholar]
  13. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Singh S, Kinnersley N, Ward P, Mills RG. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. Jama. 2000;283:1016–1024. doi: 10.1001/jama.283.8.1016. [DOI] [PubMed] [Google Scholar]
  14. Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, Jackson HC, Huson L, Ward P, Oxford JS. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. Jama. 2001;285:748–754. doi: 10.1001/jama.285.6.748. [DOI] [PubMed] [Google Scholar]
  15. (2004) Influenza and pneumococcal vaccination coverage among persons aged > or =65 years and persons aged 18–64 years with diabetes or asthma—United States, 2003. MMWR Morb Mortal Wkly Rep 53: 1007–1012 [PubMed]
  16. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med. 1995;123:518–527. doi: 10.7326/0003-4819-123-7-199510010-00008. [DOI] [PubMed] [Google Scholar]
  17. Bouree P. Immunity and immunization in elderly. Pathol Biol (Paris) 2003;51:581–585. doi: 10.1016/j.patbio.2003.09.004. [DOI] [PubMed] [Google Scholar]
  18. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med. 1994;331:778–784. doi: 10.1056/NEJM199409223311206. [DOI] [PubMed] [Google Scholar]
  19. Mullooly JP, Bennett MD, Hornbrook MC, Barker WH, Williams WW, Patriarca PA, Rhodes PH. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med. 1994;121:947–952. doi: 10.7326/0003-4819-121-12-199412150-00008. [DOI] [PubMed] [Google Scholar]
  20. Ahmed AE, Nicholson KG, Nguyen-Van-Tam JS. Reduction in mortality associated with influenza vaccine during 1989–90 epidemic. Lancet. 1995;346:591–595. doi: 10.1016/S0140-6736(95)91434-X. [DOI] [PubMed] [Google Scholar]
  21. Iob A, Brianti G, Zamparo E, Gallo T. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol Infect. 2005;133:687–693. doi: 10.1017/S0950268805003936. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol. 2004;19:353–363. doi: 10.1023/B:EJEP.0000024701.94769.98. [DOI] [PubMed] [Google Scholar]
  23. Wagner C, Popp W, Posch M, Vlasich C, Rosenberger-Spitzy A. Impact of pneumococcal vaccination on morbidity and mortality of geriatric patients: a case-controlled study. Gerontology. 2003;49:246–250. doi: 10.1159/000070405. [DOI] [PubMed] [Google Scholar]
  24. Rajagopalan S, Yoshikawa TT. Tuberculosis in the elderly. Z Gerontol Geriatr. 2000;33:374–380. doi: 10.1007/s003910070034. [DOI] [PubMed] [Google Scholar]
  25. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. Jama. 1994;271:698–702. doi: 10.1001/jama.271.9.698. [DOI] [PubMed] [Google Scholar]
  26. McShane H. Co-infection with HIV and TB: double trouble. Int J STD AIDS. 2005;16:95–100. doi: 10.1258/0956462053057576. [DOI] [PubMed] [Google Scholar]
  27. Mehta SK, Cohrs RJ, Forghani B, Zerbe G, Gilden DH, Pierson DL. Stress-induced subclinical reactivation of varicella zoster virus in astronauts. J Med Virol. 2004;72:174–179. doi: 10.1002/jmv.10555. [DOI] [PubMed] [Google Scholar]
  28. Weir E. Vaccination boosts adult immunity to varicella zoster virus. Cmaj. 2005;173:249. doi: 10.1503/cmaj.050764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW, Jr, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–2284. doi: 10.1056/NEJMoa051016. [DOI] [PubMed] [Google Scholar]
  30. Almanzar G, Schwaiger S, Jenewein B, Keller M, Herndler-Brandstetter D, Wurzner R, Schonitzer D, Grubeck-Loebenstein B. Long-term cytomegalovirus infection leads to significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons. J Virol. 2005;79:3675–3683. doi: 10.1128/JVI.79.6.3675-3683.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Pawelec G, Akbar A, Caruso C, Solana R, Grubeck-Loebenstein B, Wikby A. Human immunosenescence: is it infectious? Immunol Rev. 2005;205:257–268. doi: 10.1111/j.0105-2896.2005.00271.x. [DOI] [PubMed] [Google Scholar]
  32. Ouyang Q, Wagner WM, Zheng W, Wikby A, Remarque EJ, Pawelec G. Dysfunctional CMV-specific CD8(+) T cells accumulate in the elderly. Exp Gerontol. 2004;39:607–613. doi: 10.1016/j.exger.2003.11.016. [DOI] [PubMed] [Google Scholar]
  33. Holtappels R, Podlech J, Pahl-Seibert MF, Julch M, Thomas D, Simon CO, Wagner M, Reddehase MJ. Cytomegalovirus misleads its host by priming of CD8 T cells specific for an epitope not presented in infected tissues. J Exp Med. 2004;199:131–136. doi: 10.1084/jem.20031582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Saurwein-Teissl M, Lung TL, Marx F, Gschosser C, Asch E, Blasko I, Parson W, Bock G, Schonitzer D, Trannoy E, Grubeck-Loebenstein B. Lack of antibody production following immunization in old age: association with CD8(+)CD28(−) T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol. 2002;168:5893–5899. doi: 10.4049/jimmunol.168.11.5893. [DOI] [PubMed] [Google Scholar]
  35. Steger MM, Maczek C, Berger P, Grubeck-Loebenstein B. Vaccination against tetanus in the elderly: do recommended vaccination strategies give sufficient protection. Lancet. 1996;348:762. doi: 10.1016/S0140-6736(05)65680-2. [DOI] [PubMed] [Google Scholar]
  36. Hainz U, Aigner K, Asch E, Berger P, Bohmer F, Feldkircher B, Horwath B, Jenewein B, Kassal H, Kistner O, Mack H, Pfeiffer KP, Pils K, Plank J, Renner D, Saurwein-Teissl M, Schwanzer E, Trieb K, Grubeck-Loebenstein B. Vaccine protection in the elderly: are Austrian seniors adequately protected by vaccinations? Wien Klin Wochenschr. 2002;114:187–193. [PubMed] [Google Scholar]
  37. Hainz U, Jenewein B, Asch E, Pfeiffer KP, Berger P, Grubeck-Loebenstein B. Insufficient protection for healthy elderly adults by tetanus and TBE vaccines. Vaccine. 2005;23:3232–3235. doi: 10.1016/j.vaccine.2005.01.085. [DOI] [PubMed] [Google Scholar]
  38. Grubeck-Loebenstein B, Berger P, Saurwein-Teissl M, Zisterer K, Wick G. No immunity for the elderly. Nat Med. 1998;4:870. doi: 10.1038/nm0898-870b. [DOI] [PubMed] [Google Scholar]
  39. Gergen PJ, McQuillan GM, Kiely M, Ezzati-Rice TM, Sutter RW, Virella G. A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med. 1995;332:761–766. doi: 10.1056/NEJM199503233321201. [DOI] [PubMed] [Google Scholar]
  40. Cherry JD. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics. 2005;115:1422–1427. doi: 10.1542/peds.2004-2648. [DOI] [PubMed] [Google Scholar]
  41. Mertens PL, Stals FS, Schellekens JF, Houben AW, Huisman J. An epidemic of pertussis among elderly people in a religious institution in The Netherlands. Eur J Clin Microbiol Infect Dis. 1999;18:242–247. doi: 10.1007/s100960050271. [DOI] [PubMed] [Google Scholar]
  42. Kunz C. TBE vaccination and the Austrian experience. Vaccine. 2003;21(Suppl 1):S50–S55. doi: 10.1016/S0264-410X(02)00813-7. [DOI] [PubMed] [Google Scholar]
  43. Rendi-Wagner P, Kundi M, Zent O, Banzhoff A, Jaehnig P, Stemberger R, Dvorak G, Grumbeck E, Laaber B, Kollaritsch H. Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3 years following the last immunisation. Vaccine. 2004;23:427–434. doi: 10.1016/j.vaccine.2004.07.002. [DOI] [PubMed] [Google Scholar]
  44. Steffen R, Kane MA, Shapiro CN, Billo N, Schoellhorn KJ, van Damme P. Epidemiology and prevention of hepatitis A in travelers. Jama. 1994;272:885–889. doi: 10.1001/jama.272.11.885. [DOI] [PubMed] [Google Scholar]
  45. Steffen R. Hepatitis A and hepatitis B: risks compared with other vaccine preventable diseases and immunization recommendations. Vaccine. 1993;11:518–520. doi: 10.1016/0264-410X(93)90221-I. [DOI] [PubMed] [Google Scholar]
  46. Hopperus Buma AP, van Doornum GJ, Veltink RL, van Ameijden EJ, Leentvaar-Kuijpers A, Coutinho RA. Immunogenicity of an inactivated hepatitis A vaccine in Dutch United Nations troops. Vaccine. 1997;15:1413–1417. doi: 10.1016/S0264-410X(97)00048-0. [DOI] [PubMed] [Google Scholar]
  47. Wolters B, Junge U, Dziuba S, Roggendorf M. Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine. 2003;21:3623–3628. doi: 10.1016/S0264-410X(03)00399-2. [DOI] [PubMed] [Google Scholar]
  48. Reuman PD, Kubilis P, Hurni W, Brown L, Nalin D. The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults. Vaccine. 1997;15:1157–1161. doi: 10.1016/S0264-410X(96)00310-6. [DOI] [PubMed] [Google Scholar]
  49. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K. Persistence of neutralizing antibody 30–35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ. 1981;59:895–900. [PMC free article] [PubMed] [Google Scholar]
  50. Martin M, Weld LH, Tsai TF, Mootrey GT, Chen RT, Niu M, Cetron MS. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis. 2001;7:945–951. doi: 10.3201/eid0706.010605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Aspinall R, Andrew D. Thymic involution in aging. J Clin Immunol. 2000;20:250–256. doi: 10.1023/A:1006611518223. [DOI] [PubMed] [Google Scholar]
  52. George AJ, Ritter MA. Thymic involution with ageing: obsolescence or good housekeeping? Immunol Today. 1996;17:267–272. doi: 10.1016/0167-5699(96)80543-3. [DOI] [PubMed] [Google Scholar]
  53. Swain S, Clise-Dwyer K, Haynes L. Homeostasis and the age-associated defect of CD4 T cells. Semin Immunol. 2005;17:370–377. doi: 10.1016/j.smim.2005.05.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Kohler S, Wagner U, Pierer M, Kimmig S, Oppmann B, Mowes B, Julke K, Romagnani C, Thiel A. Postthymic in vivo proliferation of naive CD4+ T cells constrains the TCR repertoire in healthy human adults. Eur J Immunol. 2005;35:1987–1994. doi: 10.1002/eji.200526181. [DOI] [PubMed] [Google Scholar]
  55. LeMaoult J, Messaoudi I, Manavalan JS, Potvin H, Nikolich-Zugich D, Dyall R, Szabo P, Weksler ME, Nikolich-Zugich J. Age-related dysregulation in CD8 T cell homeostasis: kinetics of a diversity loss. J Immunol. 2000;165:2367–2373. doi: 10.4049/jimmunol.165.5.2367. [DOI] [PubMed] [Google Scholar]
  56. Stulnig TM, Klocker H, Harwood HJ, Jr, Jurgens G, Schonitzer D, Jarosch E, Huber LA, Amberger A, Wick G. In vivo LDL receptor and HMG-CoA reductase regulation in human lymphocytes and its alterations during aging. Arterioscler Thromb Vasc Biol. 1995;15:872–878. doi: 10.1161/01.atv.15.7.872. [DOI] [PubMed] [Google Scholar]
  57. Zanni F, Vescovini R, Biasini C, Fagnoni F, Zanlari L, Telera A, Di Pede P, Passeri G, Pedrazzoni M, Passeri M, Franceschi C, Sansoni P. Marked increase with age of type 1 cytokines within memory and effector/cytotoxic CD8+ T cells in humans: a contribution to understand the relationship between inflammation and immunosenescence. Exp Gerontol. 2003;38:981–987. doi: 10.1016/S0531-5565(03)00160-8. [DOI] [PubMed] [Google Scholar]
  58. Grubeck-Loebenstein B, Wick G. The aging of the immune system. Adv Immunol. 2002;80:243–284. doi: 10.1016/S0065-2776(02)80017-7. [DOI] [PubMed] [Google Scholar]
  59. Effros RB, Cai Z, Linton PJ. CD8 T cells and aging. Crit Rev Immunol. 2003;23:45–64. doi: 10.1615/CritRevImmunol.v23.i12.30. [DOI] [PubMed] [Google Scholar]
  60. Goronzy JJ, Fulbright JW, Crowson CS, Poland GA, O'Fallon WM, Weyand CM. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol. 2001;75:12182–12187. doi: 10.1128/JVI.75.24.12182-12187.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Wikby A, Johansson B, Olsson J, Lofgren S, Nilsson BO, Ferguson F. Expansions of peripheral blood CD8 T-lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study. Exp Gerontol. 2002;37:445–453. doi: 10.1016/S0531-5565(01)00212-1. [DOI] [PubMed] [Google Scholar]
  62. Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244–254. doi: 10.1111/j.1749-6632.2000.tb06651.x. [DOI] [PubMed] [Google Scholar]
  63. Schwaiger S, Wolf AM, Robatscher P, Jenewein B, Grubeck-Loebenstein B. IL-4-producing CD8+ T cells with a CD62L++(bright) phenotype accumulate in a subgroup of older adults and are associated with the maintenance of intact humoral immunity in old age. J Immunol. 2003;170:613–619. doi: 10.4049/jimmunol.170.1.613. [DOI] [PubMed] [Google Scholar]
  64. Herndler-Brandstetter D, Schwaiger S, Veel E, Fehrer C, Cioca DP, Almanzar G, Keller M, Pfister G, Parson W, Wurzner R, Schonitzer D, Henson SM, Aspinall R, Lepperdinger G, Grubeck-Loebenstein B. CD25-Expressing CD8+ T Cells Are Potent Memory Cells in Old Age. J Immunol. 2005;175:1566–1574. doi: 10.4049/jimmunol.175.3.1566. [DOI] [PubMed] [Google Scholar]
  65. McGlauchlen KS, Vogel LA. Ineffective humoral immunity in the elderly. Microbes Infect. 2003;5:1279–1284. doi: 10.1016/j.micinf.2003.09.001. [DOI] [PubMed] [Google Scholar]
  66. Johnson SA, Cambier JC. Ageing, autoimmunity and arthritis: senescence of the B cell compartment – implications for humoral immunity. Arthritis Res Ther. 2004;6:131–139. doi: 10.1186/ar1180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Aydar Y, Balogh P, Tew JG, Szakal AK. Age-related depression of FDC accessory functions and CD21 ligand-mediated repair of co-stimulation. Eur J Immunol. 2002;32:2817–2826. doi: 10.1002/1521-4141(2002010)32:10<2817::AID-IMMU2817>3.0.CO;2-Z. [DOI] [PubMed] [Google Scholar]
  68. Eaton SM, Burns EM, Kusser K, Randall TD, Haynes L. Age-related defects in CD4 T cell cognate helper function lead to reductions in humoral responses. J Exp Med. 2004;200:1613–1622. doi: 10.1084/jem.20041395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Levine MM, Sztein MB. Vaccine development strategies for improving immunization: the role of modern immunology. Nat Immunol. 2004;5:460–464. doi: 10.1038/ni0504-460. [DOI] [PubMed] [Google Scholar]
  70. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med. 2005;11:S63–S68. doi: 10.1038/nm1210. [DOI] [PubMed] [Google Scholar]
  71. Barouch DH, Santra S, Steenbeke TD, Zheng XX, Perry HC, Davies ME, Freed DC, Craiu A, Strom TB, Shiver JW, Letvin NL. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol. 1998;161:1875–1882. [PubMed] [Google Scholar]
  72. Kutzler MA, Robinson TM, Chattergoon MA, Choo DK, Choo AY, Choe PY, Ramanathan MP, Parkinson R, Kudchodkar S, Tamura Y, Sidhu M, Roopchand V, Kim JJ, Pavlakis GN, Felber BK, Waldmann TA, Boyer JD, Weiner DB. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol. 2005;175:112–123. doi: 10.4049/jimmunol.175.1.112. [DOI] [PubMed] [Google Scholar]
  73. Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ, Crotty LE, Casazza JP, Kuruppu J, Migueles SA, Connors M, Roederer M, Douek DC, Koup RA. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood. 2003;101:2711–2720. doi: 10.1182/blood-2002-07-2103. [DOI] [PubMed] [Google Scholar]
  74. Pawelec G, Barnett Y, Forsey R, Frasca D, Globerson A, McLeod J, Caruso C, Franceschi C, Fulop T, Gupta S, Mariani E, Mocchegiani E, Solana R. T cells and aging, January 2002 update. Front Biosci. 2002;7:d1056–d1183. doi: 10.2741/a831. [DOI] [PubMed] [Google Scholar]
  75. Naylor K, Li G, Vallejo AN, Lee WW, Koetz K, Bryl E, Witkowski J, Fulbright J, Weyand CM, Goronzy JJ. The influence of age on T cell generation and TCR diversity. J Immunol. 2005;174:7446–7452. doi: 10.4049/jimmunol.174.11.7446. [DOI] [PubMed] [Google Scholar]
  76. Spaulding C, Guo W, Effros RB. Resistance to apoptosis in human CD8+ T cells that reach replicative senescence after multiple rounds of antigen-specific proliferation. Exp Gerontol. 1999;34:633–644. doi: 10.1016/S0531-5565(99)00033-9. [DOI] [PubMed] [Google Scholar]
  77. Colonna-Romano G, Bulati M, Aquino A, Scialabba G, Candore G, Lio D, Motta M, Malaguarnera M, Caruso C. B cells in the aged: CD27, CD5, and CD40 expression. Mech Ageing Dev. 2003;124:389–393. doi: 10.1016/S0047-6374(03)00013-7. [DOI] [PubMed] [Google Scholar]
  78. Lazuardi L, Jenewein B, Wolf AM, Pfister G, Tzankov A, Grubeck-Loebenstein B. Age-related loss of naive T cells and dysregulation of T-cell/B-cell interactions in human lymph nodes. Immunology. 2005;114:37–43. doi: 10.1111/j.1365-2567.2004.02006.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Mattila PS, Tarkkanen J. Age-associated changes in the cellular composition of the human adenoid. Scand J Immunol. 1997;45:423–427. doi: 10.1046/j.1365-3083.1997.d01-417.x. [DOI] [PubMed] [Google Scholar]
  80. Weksler ME, Szabo P. The effect of age on the Bcell repertoire. J Clin Immunol. 2000;20:240–249. doi: 10.1023/A:1006659401385. [DOI] [PubMed] [Google Scholar]
  81. LeMaoult J, Szabo P, Weksler ME. Effect of age on humoral immunity, selection of the B-cell repertoire and B-cell development. Immunol Rev. 1997;160:115–126. doi: 10.1111/j.1600-065X.1997.tb01032.x. [DOI] [PubMed] [Google Scholar]

Articles from Wiener Medizinische Wochenschrift (1946) are provided here courtesy of Nature Publishing Group

RESOURCES